DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

86.06 1.65 −1.88%
Market cap
$33.1B
P/E
33.2×
Fwd P/E
29.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a

DexCom, Inc. (DXCM) Current ratio

Alert me on Current ratio

DexCom, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 1.7×, down 0.1× from fiscal 2025 (1.9×). Over the past ten years it has ranged from 1.5× (fiscal 2024) to 7.6× (fiscal 2018); the current reading is higher than 18% of that period. That is below the Medical Devices industry median of 2.5× and below the Healthcare sector median of 3.0×.

Current ratio, annual

Embed this chart

Annual newest first

Period Current ratio Change
FY2025 1.9× 28.31%
FY2024 1.5× (48.42%)
FY2023 2.8× 42.60%
FY2022 2.0× (60.98%)
FY2021 5.1× (8.35%)
FY2020 5.6× 2.00%
FY2019 5.5× (28.45%)
FY2018 7.6× 42.53%
FY2017 5.4× 96.07%
FY2016 2.7× (20.91%)

Quarterly newest first

Period Current ratio Change
Jun 2026 1.7× (11.02%)
Mar 2026 1.9× 3.47%
Dec 2025 1.9× 20.32%
Sep 2025 1.6× 2.91%
42 more quarters

Against its own ten years

Low 1.5× High 7.6×
Ten-year median 3.5×
Current reading's percentile 18

Current ratio against peers

What Current ratio is

Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.

Current Assets (Total) ÷ Current Liabilities (Total)

The full definition of Current ratio →

More on DXCM